Kickstart your research with key insights from a selection of transcripts available within our Third Bridge Library below.
Organon – Deleveraging Strategy & Long-term Growth Sustainability
Transcript key insights:
- Expert assesses Organon's business model as fundamentally broken, citing a critical failure to fund R&D, which contradicts the company's stated mission as a dedicated women's health innovation company
- The recent dividend cut to accelerate deleveraging was noted as starving Organon of essential funds for business development, severely hindering its prospects for necessary long-term organic and inorganic growth
- It was indicated that selling the declining established brands portfolio is the necessary path to fund a competitive pipeline – a strategic move that Organon appears be hesitant to undertake
- Expert emphasises securing the five-year label extension for Nexplanon within 12-18 months is the single most critical milestone for defending the franchise and maintaining company viability
- Recent acquisitions such as Vtama were deemed insufficient to alter the growth trajectory, while pipeline gaps from the OG-6219 failure left no significant near-term drivers beyond the fertility franchise
Already a client? Continue reading the full interview.
Organon – Women's Health Market Update, Biosimilar Competition & Regulatory Dynamics
Transcript key insights:
- Organon's women's health portfolio faces challenges. Regulatory hurdles in women's health drug development, particularly for maternal-fetal treatments, create significant barriers to innovation and investment in the field
- Expert agrees with management that Nexplanon is unlikely to experience generic competition right after losing exclusivity due to the complex technology, which is difficult to replicate
- Jada system, while innovative, might have limited scalability due to training requirements and emerging competition from new postpartum haemorrhage treatments and predictive devices
- Organon's biosimilar portfolio shows potential for growth as more biologics come off patent. Organon's strategy to focus on diseases disproportionately affecting women, such as migraines, aligns with its initial goals but may not fully address exclusively female health issues
- Expert thinks Organon is at an inflection point where they must decide on what its future identity will look like – as a women’s health-focused company, or not. 2024 US presidential election may also have significant impact on momentum in women’s health
Already a client? Continue reading the full interview.
Organon – More Than a Women's Health Business?
Transcript key insights:
- Organon must face its identity crisis and decide whether women's health remains the focus or pivot from an R&D identity to M&A. Expert believes this is more lucrative
- Elonva is a "distraction". Organon should shift to reliability and relationship-building for cash-cow Follistim, which has struggled with supply. Expert doesn't believe the company is ready to combat biosimilar entrants in the fertility space
- Nexplanon's five-year indication likely won't significantly boost sales, as clinical bodies already recommend extended use. Older demographic should be target market, but will be harder to capture. Nexplanon unlikely to face generic entrant anytime soon. Complex applicator development and mandatory training programmes are major barriers to entry
- 1-2 biosimilar launches per year is reasonable, but specialist suggests the biosimilars medical affairs team is superfluous and should be supplemented with sales-only
- Dermavant shows little synergy with Organon's portfolio and may require restructuring and conversion of established brand teams
Already a client? Continue reading the full interview.
Not yet a Third Bridge client? Request a free trial to experience the expert insights relied upon by the world's decision makers.
